niftify.in

Mint

Top Stock Recommendations: Dharmesh Shah of ICICI Securities suggests buying Kajaria Ceramics, and Natco Pharma tomorrow

Top Stock Recommendations: Dharmesh Shah of ICICI Securities has recommended two stocks to buy this week - Kajaria Ceramics, and Natco Pharma.

Business Line

Natco Pharma’s Canadian arm invests $8 million in eGenesis

eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs

The Economic Times

Natco Pharma acquires 40 million shares in eGenesis Inc

Natco Pharma's Canadian subsidiary has acquired 40 million shares in eGenesis Inc. for USD 8 million. eGenesis is a biotechnology company developing human-compatible organs for transplant through xenotransplantation. This investment aims to support eGenesis' pioneering work in kidney, liver, and heart transplants, potentially addressing the global transplant shortage.

Business Standard

Natco Pharma stock rises 3% after subsidiary invests $8 mn in biotech firm

Natco Pharma share price rose after the company on Wednesday announced that its wholly owned Canadian subsidiary, NATCO Pharma Inc, has made an investment of $8 million in eGenesis

CNBC TV18

Natco Pharma gains 3% on $8 million investment in US biotech firm eGenesis

Natco Pharma shares rose nearly 3% after its Canadian subsidiary invested $8 million in US-based eGenesis, a biotech firm pioneering xenotransplantation. The deal enhances Natco’s presence in cutting-edge therapeutic programmes.

Business Line

NATCO Pharma’s Canadian arm invests $8M in Xenotransplantation pioneer

NATCO Pharma’s shares fall 0.38% to ₹1,524.80 on NSE

The Economic Times

Natco Pharma shares jump 5% as company files for generic cancer drug approval with USFDA

Natco Pharma shares surged 5% to Rs 1,569 after filing an ANDA with the US FDA for a generic cancer drug. The company aims for 180 days of marketing exclusivity.

Mint

Natco Pharma share price hits 52-week high after 90% rally year to date. Buy, Sell or Hold?

Stock Market Today: Natco Pharma share price gained more than 7% to scale 52 week highs on Thursday during the intraday trades. The robust US sales growth led by Revlimid generics is driving earnings. Should you Buy, Sell or Hold the stock?

Business Line

Natco Pharma mulling acquisition in RoW market to strengthen base business

Hyderabad-based Natco has been taking steps to expand its reach and recently invested approximately $2 million in Cellogen Therapeutics Private Ltd, a Delhi based biotech start-up